In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Verona Pharma Plc (NASDAQ: VRNA), with a price target of $56. The company’s shares opened today at $12.09, close to its 52-week low of $10.16.
According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -3.6% and a 38.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Global Blood Therapeutics.
Currently, the analyst consensus on Verona Pharma Plc is a Moderate Buy with an average price target of $41.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.55 and a one-year low of $10.16. Currently, Verona Pharma Plc has an average volume of 3,430.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. Verona Pharma’s product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.
